CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

D Sarker; S Blagden; N Cook; TR Evans; R Plummer; A Angelakas; S Bashir; S El Badri; L Mavroeidis; C Morton; A Muhith; M White; R Dixon; E Garric; J Mann; I Matthews; U Banerji

doi:10.1158/1538-7445.AM2023-CT094

CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

D Sarker, S Blagden, N Cook, TR Evans, R Plummer, A Angelakas, S Bashir, S El Badri, L Mavroeidis, C Morton, A Muhith, M White, R Dixon, E Garric, J Mann, I Matthews, U Banerji

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	CT094-CT094
Number of pages	3
Journal	Cancer Research
Volume	83
Issue number	8_Supplement
DOIs	https://doi.org/10.1158/1538-7445.AM2023-CT094
Publication status	Published - 15 Apr 2023

Access to Document

10.1158/1538-7445.AM2023-CT094

Cite this

Sarker, D., Blagden, S., Cook, N., Evans, TR., Plummer, R., Angelakas, A., Bashir, S., El Badri, S., Mavroeidis, L., Morton, C., Muhith, A., White, M., Dixon, R., Garric, E., Mann, J., Matthews, I., & Banerji, U. (2023). CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors. Cancer Research, 83(8_Supplement), CT094-CT094. https://doi.org/10.1158/1538-7445.AM2023-CT094

@article{d24e5d6b7aa546ceb08af17514e37581,

title = "CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors",

author = "D Sarker and S Blagden and N Cook and TR Evans and R Plummer and A Angelakas and S Bashir and {El Badri}, S and L Mavroeidis and C Morton and A Muhith and M White and R Dixon and E Garric and J Mann and I Matthews and U Banerji",

year = "2023",

month = apr,

day = "15",

doi = "10.1158/1538-7445.AM2023-CT094",

language = "English",

volume = "83",

pages = "CT094--CT094",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "8_Supplement",

}

Sarker, D, Blagden, S, Cook, N, Evans, TR, Plummer, R, Angelakas, A, Bashir, S, El Badri, S, Mavroeidis, L, Morton, C, Muhith, A, White, M, Dixon, R, Garric, E, Mann, J, Matthews, I & Banerji, U 2023, 'CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors', Cancer Research, vol. 83, no. 8_Supplement, pp. CT094-CT094. https://doi.org/10.1158/1538-7445.AM2023-CT094

CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors. / Sarker, D; Blagden, S; Cook, N et al.
In: Cancer Research, Vol. 83, No. 8_Supplement, 15.04.2023, p. CT094-CT094.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

AU - Sarker, D

AU - Blagden, S

AU - Cook, N

AU - Evans, TR

AU - Plummer, R

AU - Angelakas, A

AU - Bashir, S

AU - El Badri, S

AU - Mavroeidis, L

AU - Morton, C

AU - Muhith, A

AU - White, M

AU - Dixon, R

AU - Garric, E

AU - Mann, J

AU - Matthews, I

AU - Banerji, U

PY - 2023/4/15

Y1 - 2023/4/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001018089900077&DestLinkType=FullRecord&DestApp=WOS

UR - https://www.mendeley.com/catalogue/35bd296d-91ba-35a7-90ab-583c853fe4d0/

U2 - 10.1158/1538-7445.AM2023-CT094

DO - 10.1158/1538-7445.AM2023-CT094

M3 - Meeting Abstract

SN - 0008-5472

VL - 83

SP - CT094-CT094

JO - Cancer Research

JF - Cancer Research

IS - 8_Supplement

ER -

CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors

Access to Document

Other files and links

Cite this